Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment
- PMID: 1633889
- DOI: 10.1016/s0015-0282(16)55188-7
Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment
Erratum in
- Fertil Steril 1993 Jun;59(6):1334
Abstract
Objective: To overview the world literature on ovarian hyperstimulation syndrome (OHSS) and modes of prevention and treatment of OHSS.
Study selection: All the pertinent literature on OHSS, its prevention, and strategies for treatment were reviewed.
Prevention: Key to prevention is proper identification of the population at risk, which includes women with either the hormonal or the morphological signs of polycystic ovarian disease, high serum estradiol (E2) before human chorionic gonadotropin (hCG) administration (E2 greater than 4,000 pg/mL), multiple follicular response (greater than 35), younger age, and lean habitus. When a high risk situation is recognized, ovulatory dose of hCG may be reduced, avoided (with cycle cancellation), or substituted by gonadotropin-releasing hormone or its agonist. Luteal support with hCG is to be bypassed. To minimize risk of OHSS, endogenous pregnancy-drived hCG may be eluded by judicious cryopreservation of all embryos. Last, follicular aspiration will allow higher levels of E2 and larger number of follicles to be matured with lesser risk of OHSS than conventional ovulation induction without follicular aspiration.
Treatment: In-house for the severe and intensive care for the critical form. Meticulous fluid and electrolyte balance using both crystalloids and colloids (albumin) until hemoconcentration abates. Paracentesis is indicated for tight ascites, deteriorating kidney functions, and symptomatic relief. Diuretics may be prudently used once hemodilution is achieved. Dopamine drip may be used as a renal rescue, whereas heparin is indicated for thromboembolic phenomena and surgery reserved for abdominal catastrophies. Therapeutic interruption of an early gestation may be lifesaving when all other measures have failed.
Conclusions: Although severe and critical OHSS may not be completely avoided, early recognition of high-risk factors, judicious prevention schemes, and treatment strategies should reduce the complication and long-term sequelae of this iatrogenic syndrome.
Republished in
-
Reprint of: Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment.Fertil Steril. 2019 Oct;112(4 Suppl1):e209-e221. doi: 10.1016/j.fertnstert.2019.08.094. Fertil Steril. 2019. PMID: 31623736 No abstract available.
Similar articles
-
Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.Hum Reprod. 2013 Sep;28(9):2522-8. doi: 10.1093/humrep/det124. Epub 2013 Apr 30. Hum Reprod. 2013. PMID: 23633553
-
The prevention of ovarian hyperstimulation syndrome.J Obstet Gynaecol Can. 2014 Nov;36(11):1024-1033. doi: 10.1016/S1701-2163(15)30417-5. J Obstet Gynaecol Can. 2014. PMID: 25574681 Review. English, French.
-
A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.Taiwan J Obstet Gynecol. 2015 Oct;54(5):583-7. doi: 10.1016/j.tjog.2015.08.012. Taiwan J Obstet Gynecol. 2015. PMID: 26522115
-
Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol.PLoS One. 2016 Mar 7;11(3):e0149615. doi: 10.1371/journal.pone.0149615. eCollection 2016. PLoS One. 2016. PMID: 26950065 Free PMC article.
-
Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.Hum Reprod Update. 2002 Nov-Dec;8(6):559-77. doi: 10.1093/humupd/8.6.559. Hum Reprod Update. 2002. PMID: 12498425 Review.
Cited by
-
[Jugular vein thrombosis caused by hypercoagulability following in-vitro fertilization-activated protein C resistance and immobilization].HNO. 2013 Mar;61(3):250-5. doi: 10.1007/s00106-011-2460-3. HNO. 2013. PMID: 22532279 Review. German.
-
Ovarian hyperstimulation syndrome.J Hum Reprod Sci. 2011 May;4(2):70-5. doi: 10.4103/0974-1208.86080. J Hum Reprod Sci. 2011. PMID: 22065820 Free PMC article.
-
Nephrotic sydrome developing in severe ovarian hyperstimulation syndrome.Int J Fertil Steril. 2014 Jan;7(4):345-8. Epub 2013 Dec 22. Int J Fertil Steril. 2014. PMID: 24520505 Free PMC article.
-
Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: a phase 3 open-label follow-up to Main Study.Reprod Biol Endocrinol. 2016 Jun 10;14(1):31. doi: 10.1186/s12958-016-0164-y. Reprod Biol Endocrinol. 2016. PMID: 27287439 Free PMC article. Clinical Trial.
-
Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization.J Assist Reprod Genet. 2002 Apr;19(4):159-63. doi: 10.1023/a:1014828027282. J Assist Reprod Genet. 2002. PMID: 12036082 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical